Stockscreener 앱 받기
5.34
1.29%
-0.08
전일 마감가:
$5.42
열려 있는:
$5.26
하루 거래량:
323.18K
Relative Volume:
0.31
시가총액:
$267.53M
수익:
$124.00K
순이익/손실:
$-49.99M
주가수익비율:
-3.1598
EPS:
-1.69
순현금흐름:
$-31.03M
1주 성능:
+0.00%
1개월 성능:
+12.39%
6개월 성능:
+6.15%
1년 성능:
-49.95%
1일 변동 폭
$5.18
$5.41
1주일 범위
$5.18
$5.935
52주 변동 폭
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
CADL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.34 | 256.02M | 124.00K | -49.99M | -31.03M | -1.69 |
|
ONC
Beigene Ltd Adr
|
241.99 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.87 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.32 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.80 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - Yahoo Finance
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewswire
Breakthrough Phase 3 Results: First Successful Prostate Cancer Trial in 20 Years Shows 30% Lower Recurrence Risk - Stock Titan
Best Momentum Stocks to Buy for May 19th - The Globe and Mail
New Strong Buy Stocks for May 19th - The Globe and Mail
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
CADL To Present Prostate Cancer Trial Data, RMD's Q3 Revenue Climbs 8%, AUNA On Watch... - RTTNews
Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics - TipRanks
Candel Therapeutics Reports Strong Q1 2025 Results - TipRanks
CADL's Cash Reserves Projected to Last Until Early 2027 | CADL S - GuruFocus
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - NewsBreak: Local News & Alerts
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish By Stocktwits - Investing.com India
Small cap wrap: Candel Therapeutics, Nevis Brands, Fineqia, Voyageur Pharmaceuticals, atai... - Proactive financial news
Candel Therapeutics (CADL) Reports Q1 Earnings and Cash Reserves - GuruFocus
Market movers: Coinbase, Hertz, Candel Therapeutics, JD Sports... - Proactive Investors
Cardell Flat on Q1 - Baystreet.ca
Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drug - Proactive financial news
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Wells Fargo & Company MN Increases Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Barclays PLC Purchases 5,629 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) Expected to Announce Earnings on Tuesday - Defense World
Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Candel Therapeutics to present at upcoming healthcare conferences - Proactive financial news
Candel Therapeutics to Present at Upcoming Investor Conferences in May and June 2025 - Nasdaq
Candel Therapeutics Inc [CADL] stock for 396,995 USD was sold by Nichols William Garrett - knoxdaily.com
Is Candel Therapeutics Inc (CADL) worth investing in despite its overvalued state? - uspostnews.com
LPL Financial LLC Makes New Investment in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Financial Metrics Check: Candel Therapeutics Inc (CADL)’s Ratios for Trailing Twelve Months - DWinneX
Geode Capital Management LLC Grows Stock Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
S3e01 Life Changing Innovation with Paul Peter Tak, CEO of Candel Therapeutics - iHeart
A new trading data show Candel Therapeutics Inc (CADL) is showing positive returns. - Sete News
Candel Therapeutics to Present Prostate Cancer Trial Data By Investing.com - Investing.com South Africa
Candel Therapeutics to Present Prostate Cancer Trial Data - Investing.com
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - The Manila Times
Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting - Nasdaq
Candel Therapeutics Announces Oral Presentation of Positive - GlobeNewswire
Major Phase 3 Trial Results: Breakthrough Prostate Cancer Treatment Data to be Revealed at ASCO 2025 - Stock Titan
Candel Therapeutics to present Phase 3 prostate cancer data at 2025 ASCO Annual Meeting - Proactive Investors
Technical analysis of Candel Therapeutics Inc (CADL) stock chart patterns - uspostnews.com
How To Trade (CADL) - news.stocktradersdaily.com
Candel Therapeutics (NASDAQ:CADL) Earns “Buy” Rating from HC Wainwright - Defense World
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
자본화:
|
볼륨(24시간):